#Budget2019 #JetAirways #TailorMadeBiz

SENSEX
NIFTY 50
Hang Seng
Taiwan Weighted
MCX GOLD AUG 05
MCX SILVER JUL 05
USD/INR
EUR/INR80.0630

SENSEX
NIFTY 50
NIFTY MIDCAP 100
S&P BSE MIDCAP
Hang Seng
Taiwan Weighted
DAX
Nasdaq
MCX GOLD AUG 05
MCX SILVER JUL 05
MCX CRUDEOIL JUL 19
MCX NATURALGAS JUN 25
USD/INR
EUR/INR
GBP/INR
JPY/INR

10 things you need to know before the opening bell on June 25

Asian Market: Dollar falls with yields as more Fed talk awaited

Oil prices steady, US-Iran tensions remain in focus

Rupee opened flat at 69.58/$ in early trade

Business

Orchid Pharmaceuticals investment was a mistake, says billionaire Adar Poonawalla

Updated : October 11, 2018 12:09 PM IST

No merit in acquiring Panacea Biotech: Adar Poonawalla

Promoter of Panacea Biotech want to continue running the company: Adar Poonawalla

No plans to do anything with stake in Panacea Biotech: Adar Poonawalla

Billionaire Adar Poonawalla, the CEO of one of the world's largest vaccine maker Serum Institute of India, also has regrets. In an interaction with CNBC-TV18, Poonawalla said his biggest mistake was investing in Orchid Pharma.

"Investments in Orchid Pharmaceuticals was perhaps the single mistake we have ever made," said Adar Poonawalla on Thursday.

Adar's father Cyrus Poonawalla and his affiliated firms had acquired around 14 percent stake in Orchid over a period of time. Cyrus had later filed a Company Petition alleging certain acts of oppression and mismanagement in the affairs of Orchid Pharma .

When asked about acquiring Orchid, he said, “We tried to but we had issues with the existing CEO and promoter and that didn’t work out.”

“The debt that they kept taking was without anyone’s consent and they sort of went further into a mess. We just now are getting out of it at whatever value we can,” he said.

Talking about his investments and tie-ups with companies in the listed space, Adar Poonawala said his nearly 15 percent stake in Panacea Biotech is just strategic while tie-up with Cipla is only limited to South Africa.

On the business front, Poonawala said, “We are going to stick to making vaccines and at the most diversify into our new NBFC that we have formed to enter the financial services area.”

Have you signed up for Primo, our daily newsletter? It has all the stories and data on the market, business, economy and tech that you need to know.

primo org

Have you signed up for Primo, our daily newsletter?

It has all the stories and data on the market, business, economy and tech that you need to know.

To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more

You May Also Like

Indian telcos may need to invest Rs 1 lakh crore on optical fibre in 2-3 years for 5G, says Crisil

Indian telcos may need to invest Rs 1 lakh crore on optical fibre in 2-3 years for 5G, says Crisil

Reliance Jio, BSNL drive telecom subscriber base to 1,183.77 million in April

Reliance Jio, BSNL drive telecom subscriber base to 1,183.77 million in April

BNP Paribas Cardif to sell 2.5% stake in SBI Life for Rs 1,625 crore

BNP Paribas Cardif to sell 2.5% stake in SBI Life for Rs 1,625 crore

Trending on CNBC-TV18

Live TV

recommended for you